Pfizer

Residents and hotel guests in Manhattan were gradually allowed to return to cordoned streets after an under-construction high-rise showed structural instability, prompting evacuations and street closures. Mayor Zohran Mamdani confirmed the building is stable, but four nearby buildings remain under evacuation orders. Construction workers protested the use of non-union labor at the site.

Two columns buckled in the former Pfizer headquarters building in New York City, leading to street closures and evacuations, but the building did not collapse. The incident caused chaos for dozens of people in the area.

A high-rise under construction in Manhattan experienced structural issues, leading to evacuations and street closures. Officials stabilized the building, but some surrounding areas remain under evacuation orders. The developer, MetroLoft, attributes the damage to added weight from construction.

A partially constructed Manhattan high-rise buckled and sagged, leading to evacuations and street closures. The building has been stabilized, but some evacuations and closures remain as repairs continue. The developer attributes the damage to added weight from construction.

Crews stabilized a Manhattan high-rise under construction after columns buckled and floors sagged, leading to evacuations and street closures. The building, former Pfizer headquarters, remains under repair with some surrounding areas still evacuated. MetroLoft, the developer, attributes the damage to added weight from expanding the top floors.

An under-construction Manhattan high-rise stabilized after columns buckled, leading to lifted evacuations of nearby buildings. Emergency repairs are ongoing at the former Pfizer headquarters, now being converted into luxury apartments.

Crews are working to stabilize the former Pfizer headquarters in New York City after it was deemed structurally unsafe due to buckling support columns. Video footage shows steel bending and a slight lean in the high-rise, raising concerns of potential collapse.

An unstable building in Midtown Manhattan has caused multiple evacuations and street closures. The structure is the former Pfizer headquarters being converted into apartments.

FDNY drone images revealed buckled structural columns and damage inside a Midtown construction site, leading to evacuations and concerns about a localized collapse beneath a 10-story horizontal expansion of the Pfizer building.

Roads in Midtown Manhattan were closed due to a partial collapse of the former Pfizer building on 42nd Street, leading to a 'frozen zone' restricting traffic from 40th to 45th Street and First to Third Avenues, affecting at least 10 buildings.

The Pfizer building in Midtown Manhattan partially collapsed on Tuesday, leading to evacuations. Mayor Zohran Mamdani reported that the structure has not moved in two hours and is beginning to stabilize.

An under-construction high-rise in Manhattan remains unstable after columns buckled and floors sagged, leading to ongoing evacuations. The building, a former Pfizer headquarters being converted to luxury apartments, is still moving, prompting evacuations of nearby buildings including a school.

A 37-story building in Midtown NYC was evacuated along with seven surrounding buildings due to a safety breach causing the structure to shift and risk localized collapse. The building, located on East 42nd Street, was previously the Pfizer headquarters.

A Manhattan high-rise under construction near the Chrysler Building and Grand Central Terminal remains unstable after bricks fell and columns buckled, forcing evacuations of nearby buildings. The 1970s-era former Pfizer headquarters, being converted to luxury apartments, showed structural issues on floors 21-26 with no reported injuries.

The old Pfizer building in Manhattan, being converted into a residential development, has a history of violations. It was evacuated after structural issues caused floors 21-26 to collapse.

Reports of falling bricks and buckling columns at a Midtown Manhattan high-rise under conversion to luxury apartments forced evacuations, including a nearby school with 400 children. No injuries were reported, and city officials confirmed inspections at the 38-story former Pfizer headquarters. The building's structural issues prompted street closures and ongoing safety assessments.

Falling bricks and buckling columns at a Midtown Manhattan high-rise prompted evacuations, including a school with 400 children. The building, formerly Pfizer's headquarters, is being converted to luxury apartments. No injuries were reported, and officials emphasized safety as the priority.

Evacuations were ordered at a 33-story building under construction in Midtown Manhattan after structural beams on the 21st floor began buckling, causing upper floors to sag and bricks to fall. The incident disrupted public transportation and led to evacuations of adjoining buildings, though no injuries were reported.

Bricks fell from a Manhattan high-rise at 235 East 42nd Street, leading to evacuations and the discovery of buckled columns and sagging floors. No injuries were reported, and all construction workers were accounted for. The building, former Pfizer headquarters, is being converted into a residential rental development.

Protillion Biosciences hired Robert Hollingsworth as chief scientific officer. He previously held the same role at Shoreline Therapeutics and worked at Pfizer as vice president and chief scientific officer of cancer vaccines and immunotherapeutics.

Pfizer and Valneva plan to seek approval for a new Lyme disease vaccine, following the failure of a 1990s vaccine due to lawsuits and public fear. A survey of hunters, a high-risk group for tick exposure, found mixed reactions, with some expressing interest and others seeking more information about safety and effectiveness.

Clive Meanwell, chairman of Population Health Partners, leveraged a competitive bidding war between Pfizer and Novo Nordisk for obesity startup Metsera, which reached a $10 billion offer. He now focuses on AI-driven solutions to address large-scale health challenges through innovative technologies and business models.

Nike appointed David Denton, a former Pfizer executive, as its new CFO amid restructuring efforts. Olive and Alder Co., a natural skincare brand, will host a pop-up at Perkins Rowe. OpenAI restricted the initial release of its GPT-5.6 model to government-approved partners due to U.S. scrutiny.

Nike is replacing its CFO with David Denton, a finance veteran from Pfizer. Denton will assume the role on August 17.

Pfizer disclosed that its experimental lung cancer drug, sigvotatug vedotin, failed to show a statistically significant improvement over docetaxel in a clinical trial. The U.S. Food and Drug Administration announced a pilot program to accelerate early-stage clinical trials, aiming to reduce development timelines and counter Chinese dominance in the field.

Pfizer's experimental lung cancer drug sigvotatug vedotin failed in a clinical trial, which was expected to replace the chemotherapy docetaxel. The drug was acquired through Pfizer's $43 billion purchase of Seagen in 2023.

Pfizer CEO Albert Bourla discusses leaving Europe to pursue the American dream, highlighting the 'enormous' opportunities in the U.S. He acknowledges American society is not perfect but describes it as an 'oasis in a desert' compared to other societies.

Pfizer's CFO is stepping down to take a job in consumer goods. Cecile Guegan will serve as interim CFO starting August 16 while the company searches for a permanent replacement.

GLP-1 weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are popular, prompting competitors like Pfizer and Amgen to develop similar products. The article discusses market competition and strategies by Novo Nordisk and Eli Lilly to maintain dominance in the weight loss drug sector.

The article discusses congenital syphilis in newborns, a preventable condition with penicillin from Pfizer, and questions Abridge’s 'patient centered' claim. The author expresses frustration over preventable medical issues and emotional reactions to community stories.

The U.S. faces a shortage of Bicillin L-A, the only first-line injectable penicillin for treating syphilis in pregnant women to prevent congenital syphilis, following a Pfizer recall due to contamination. The FDA estimates normal supplies won’t return until December 2027, forcing temporary reliance on imported Lentocilin from Portugal. The shortage risks worsening disparities in congenital syphilis rates, particularly affecting Indigenous and Black infants.

The U.S. is facing a shortage of Bicillin L-A, the only U.S.-made antibiotic for treating syphilis in pregnant women to prevent congenital syphilis. Pfizer's recall of the drug due to contamination risks has delayed supply until 2027, forcing temporary reliance on imported Lentocilin. The shortage risks worsening infection rates, particularly among Indigenous and Black infants.

Chris Boshoff, a Pfizer executive, discusses efforts to revive public enthusiasm for science. The article highlights his focus on rekindling interest in scientific advancements.

The U.S. faces a shortage of Bicillin L-A, the only first-line injectable penicillin for treating syphilis in pregnant women to prevent congenital syphilis. Pfizer's recall of the drug due to contamination risks, combined with limited manufacturing capacity, has delayed supply until 2027, raising concerns about rising infection rates and disparities affecting Indigenous and Black infants.

The U.S. faces a shortage of Bicillin L-A, the only first-line injectable penicillin for treating syphilis in pregnant women to prevent congenital syphilis. Pfizer's recall of the drug due to contamination risks has delayed supply until December 2027, forcing temporary reliance on imported Lentocilin. Health experts warn the shortage could worsen infection rates and disparities, as congenital syphilis causes severe, irreversible harm to infants.

The U.S. faces a shortage of Bicillin L-A, the only first-line injectable penicillin for treating syphilis in pregnant women to prevent congenital syphilis, due to a Pfizer recall linked to contamination. The FDA projects normal supply won’t return until December 2027, exacerbating rising congenital syphilis rates and disparities among Indigenous and Black infants.

A pregnant woman in Gila County, Arizona, faced a preventable syphilis diagnosis in her newborn due to delays in receiving Bicillin L-A, an injectable penicillin critical for treating syphilis during pregnancy. Pfizer, the sole U.S. supplier, had an emergency request system in place but failed to deliver the medication in time, despite warnings from public health officials about systemic delays. The case highlights a national shortage of the drug since July 2025 and Pfizer's unfulfilled commitment to donate reserves to health departments.

An EU court adviser criticized the European Commission for insufficient transparency regarding its Covid-19 vaccine contracts, noting anonymized declarations made it impossible to assess staff impartiality. The Commission argued releasing details could lead to harassment from conspiracy theorists, while Green MEPs and over 3,000 members of the public challenged the lack of disclosure in court.

Pfizer's monthly injectable weight loss drug berobenatide showed side effects similar to Novo Nordisk's Wegovy in a mid-stage trial, with comparable rates of nausea and vomiting.

Chinese biotechnology companies are projected to market their own medications in Europe and the US within 10 to 15 years, according to analysts. Discussions among investors and analysts focus on identifying which firms will achieve international sales amid a boom in outlicensing agreements.